Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpyGlass PharmaSGP -0.59%12 EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100. Among 942 Biotechnology companies, SpyGlass Pharma ranks worse than 106157.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SpyGlass Pharma's EBITDA for the
three
months ended in Jun. 2026 was $-21.63 Mil. SpyGlass Pharma's Revenue for the
three
months ended in Jun. 2026 was $0.00 Mil. Therefore, SpyGlass Pharma's EBITDA margin for the quarter that ended in Jun. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SpyGlass Pharma EBITDA Margin % Related Terms
SpyGlass Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SpyGlass Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGP vs RIGL, NGNE, OCS: EBITDA Margin % Comparison
For the Biotechnology subindustry, SpyGlass Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpyGlass Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SpyGlass Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpyGlass Pharma (SGP) has a EBITDA Margin % of 0.00% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SpyGlass Pharma and its competitors. According to the industry distribution chart, SpyGlass Pharma ranks #999999 out of 942 companies in the Biotechnology industry.
Is SpyGlass Pharma's EBITDA Margin % too high?
SpyGlass Pharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, SpyGlass Pharma ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's EBITDA Margin % compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #999999 out of 942 companies for EBITDA Margin %. This places SpyGlass Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SpyGlass Pharma and its competitors. SpyGlass Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score
Get the complete analysis for SGP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGP has been successfully added to your 
